Table 2.

FT3 and FT4 levels, as well as their ratios, in patient groups according to age

		3–5 y	6–8 y	9–11 y	12–14 y	15–18 y	Total
Control (n = 129)	n	24	19	31	36	19	129
	FT3	4.11 ± 0.56	4.29 ± 0.43α	4.14 ± 0.38	3.89 ± 0.50α	3.93 ± 0.56	4.06 ± 0.50
	FT4	1.36 ± 0.14	1.38 ± 0.11	1.36 ± 0.14	1.33 ± 0.16	1.31 ± 0.10	1.35 ± 0.14
	FT3/FT4	3.02 ± 0.38	3.12 ± 0.31	3.07 ± 0.38	2.95 ± 0.35	3.01 ± 0.50	3.03 ± 0.38
A/Hypoplasia (n = 22)	nb	14	20	22	21	24	101
	FT3	4.15 ± 0.51	3.86 ± 0.42	3.91 ± 0.45	3.84 ± 0.60	3.52 ± 0.60	3.82 ± 0.55*
	FT4	1.95 ± 0.20**	1.81 ± 0.31**	1.76 ± 0.26**	1.85 ± 0.59**	1.90 ± 0.69**	1.85 ± 0.47**
	FT3/FT4	2.15 ± 0.25**	2.18 ± 0.30**	2.25 ± 0.39**	2.23 ± 0.34**	2.03 ± 0.30**	2.17 ± 0.33**
Central (n = 27)	nb	11	31	46	31	26	145
	FT3	3.50 ± 0.48	3.49 ± 0.53**	3.51 ± 0.64**	3.63 ± 0.64	3.46 ± 0.54	3.52 ± 0.58**
	FT4	1.24 ± 0.23	1.31 ± 0.17	1.43 ± 0.29	1.45 ± 0.30	1.49 ± 0.25	1.41 ± 0.27
	FT3/FT4	2.94 ± 0.58	2.68 ± 0.51*	2.49 ± 0.37**	2.52 ± 0.37*	2.37 ± 0.40**	2.55 ± 0.45**

Values are pg/mL (FT3) and ng/dL (FT4); mean ± standard deviation

^α P < 0.05, *P < 0.05; **P < 0.01, compared to control, respectively

^bIn A/Hypoplasia and Central, patients underwent repetitive measurements of FT3 and FT4. All the values are averaged according to the chronological age of the patients. The same patients may have average independent measurement values in more than one age category if they were evaluated over multiple years